Health Affairs September 3, 2024
Inmaculada Hernandez, Olivier J. Wouters, Emma M. Cousin, Ayuri S. Kirihennedige, Sean D. Sullivan

On August 15, 2024, the Centers for Medicare and Medicaid Services (CMS) released the negotiated prices, or Maximum Fair Prices (MFPs), for the first 10 pharmaceutical products selected for negotiation under the Inflation Reduction Act’s Medicare Drug Price Negotiation Program. These prices will be effective in 2026. CMS stated that if the MFPs had been introduced in 2023, they would have resulted in a 22% decrease in Medicare Part D net spending, or $6B. CMS also reported differences between MFPs and list prices in 2023 for each of the products. It did not, however, release information on the extent to which MFPs compared to Medicare Part D net prices at the drug level. This distinction is critical because most of...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, CMS, Congress / White House, Govt Agencies, Insurance, Medicare, Patient / Consumer, Pharma, Pharma / Biotech, Provider
Related Articles:
Allowing Medicare to Negotiate Drug Prices Remains Broadly Popular Among Voters, Though Most Are Unaware of the Law and Its Projected Savings
What Medicare Negotiation Tells Us About Drug Pricing In The U.S.
A Core Measure Set For Age-Friendly Health Care Delivery
KFF Health Tracking Poll September 2024: Support for Reducing Prescription Drug Prices Remains High, Even As Awareness of IRA Provisions Lags
Physicians vs. reimbursements: 3 updates

Share This Article